VC Executive Summary

Sanofi Ventures is the corporate venture capital arm of the global pharmaceutical giant Sanofi. It operates as a strategic investor to fund early-stage breakthroughs that align with Sanofi's long-term commercial goals.

Leadership

Jason P. Hafler: Managing Director. He shapes the overall fund strategy, capital allocations, and final investment decisions.

Investment Partners (The Primary Deal Leads)

• Cris De Luca: Partner. He focuses on AI-driven digital health, software, and healthcare IT. He is the specific lead who evaluated and managed the QuantHealth investment.

• Laia Crespo: Partner. She leads deals across early-stage biotech, therapeutic platforms, and drug development.

• Paulina Hill: Partner. She manages early-stage company building and biotech platform investments.

Execution & Diligence Team

• Christopher Gagliardi & Meg Krench: Principals. They often serve as the initial screening gatekeepers, leading deep-dive diligence and running financial modeling on deals.

• Kriti Subramanyam: Director of Investments. She evaluates newer deals in medtech and digital health services

Fund Structure & Scale

• Assets Under Management: Serves as an evergreen venture fund with total assets under management exceeding $1.4 billion

• Recent War Chest Boost: Expanded its investment capacity following a $625 million multi-year capital commitment from its parent company

• Evergreen Model: Unlike traditional fixed-term funds, all returns generated from successful portfolio exits are continually reinvested to fuel future deals.

Strategic Investment Focus

• Core Sectors: Concentrates capital on two primary verticals: Biotech / Life Sciences and Digital Health / Artificial Intelligence.

• Therapeutic Targets: Aligns deals with core pharma operations like immunology, rare diseases, neurology, and vaccines, alongside emerging spaces like ophthalmology and neuropsychiatry.

• Lifecycle Agility: Leads or participates in financing rounds across all stages of a private company's life cycle, spanning from initial Seed and Series A/B rounds up to late-stage "crossover" fundings.

Beyond Capital: Corporate Edge

• Strategic Entry Point: Identifies and backs high-risk, high-potential science too early for a traditional pharma partnership or M&A deal.

• Pharma Ecosystem Access: Portfolio companies gain direct access to Sanofi's internal capabilities, including regulatory pathways, clinical trial design, manufacturing scale, and market access experts.

Notable Portfolio Companies

• QuantHealth: Backed as an early investor to pioneer AI-enabled digital twins and clinical trial simulation platforms.

• Carbon Health: A tech-enabled modern primary care provider.

• Omada Health: A prominent virtual care and chronic condition management platform.

• Recent Deal Velocity: The firm maintains a highly active portfolio, recently participating in financing for Expedition Therapeutics

What Founders Need to Know About Partnering with Sanofi Ventures

Securing investment from a major corporate venture capital (CVC) arm like Sanofi Ventures requires understanding how they operate differently than traditional financial VCs. Use these insider details to tailor your pitch and maximize your leverage.

1. Investment Sweet Spots & Deal Sizes

• Check Sizes: Typically ranges from $5 million to $15 million for initial investments, with significant capital reserved for follow-on rounds.

• Stage Agility: They invest across the entire private lifecycle—from Seed and Series A to late-stage "crossover" rounds right before an IPO.

• Core Verticals: They heavily prioritize Biotech/Life Sciences and Digital Health/Artificial Intelligence.

• Current AI Thesis: They are explicitly deploying capital to find software solutions that accelerate clinical trial execution, target identification, and molecule design.

2. The Power of Their "Evergreen" Structure

• No Fixed Clock: Unlike traditional VC funds that must return cash to limited partners (LPs) within 10 years, Sanofi Ventures uses an evergreen model.

• Reinvested Returns: Profits from successful exits (such as Omada Health's recent IPO) go directly back into their cash reserves to fund new startups.

• Founder Alignment: This means they are not pressured to force an early or unnatural exit. They can stay patient and aligned with your long-term scientific or clinical timelines.

3. How to Navigate the CVC "Double-Bottom Line"

To win over Sanofi Ventures, founders must pitch to two distinct evaluation criteria simultaneously:

Financial Return

• Can this startup achieve a venture-scale exit via M&A or IPO?

• Does this technology directly solve a bottleneck for Sanofi’s core commercial business?

Strategic Alignment

• Must show a clear path to independent commercial sustainability.

• Must align with core areas: Immunology, Rare Diseases, Neurology, and Vaccines.

4. Strategic Benefits Beyond the Check

• Board Participation: They frequently take active Board Observer or Director seats (e.g., Partner Cris De Luca joining QuantHealth’s board) to provide hands-on governance.

• Built-in Validation: A check from Sanofi Ventures acts as an enterprise stamp of approval, making it significantly easier to close other pharma clients.

• The Inside Track: While it does not guarantee a buyout, a venture investment often serves as an informal staging ground for larger corporate partnerships or future M&A.